Contents

1 Multiple-Hypothesis Testing Strategy 1
1.1 Multiple-Testing Problems 1
1.1.1 Statistical Hypothesis Testing 1
1.1.2 Sources of Multiplicity 1
1.1.3 Multiple-Testing Taxonomy 3
1.2 Multiple-Testing Approaches 7
1.2.1 Single-Step Procedures 7
1.2.2 Stepwise Procedures 10
1.2.3 Common Gatekeeper Procedure 15
1.2.4 Tree Gatekeeping Procedure 17
1.2.5 Generalized FWER and Partitioning Testing 18
1.2.6 Procedures Controlling False Discovery Rate 21
1.3 Controversies and Challenges 24
1.3.1 Family of Errors 24
1.3.2 Interpretation of Multiple-Testing Results 25
1.3.3 The Spring Water Paradox 25
1.3.4 A Patient's Dilemma with Multiple-Testing 26
1.4 Exercises 27
Further Readings and References 28

2 Pharmaceutical Decision and Game Theory 31
2.1 Pharmaceutical Decisions 31
2.1.1 Markov Decision Process 31
2.1.2 Dynamic Programming 33
2.1.3 Clinical Development Program 34
2.1.4 R & D Portfolio Optimization 38
2.1.5 Prescription Drug Marketing 40
2.2 Pharmaceutical Games 42
2.2.1 The Game Concept 42
2.2.2 Multiple-Player Game 46
2.2.3 Queuing Game 47

2.2.4 Cooperative Games 49
2.2.5 Sequential Game 50
2.3 Implementation Challenges 53
2.4 Exercises 55
Further Readings and References 56

3 Noninferiority Trial Design 59
3.1 Concept of Noninferiority Trial 59
3.1.1 Needs for Noninferiority Design 59
3.1.2 Noninferiority Lingo 61
3.1.3 Noninferiority Design Methods 61
3.1.4 Analysis of Noninferiority Trials 65
3.2 Two-Arm Design 66
3.2.1 Fixed-Margin Method 66
3.2.2 λ-Portion Method 69
3.2.3 Synthesis Method 70
3.2.4 Paired Data 74
3.3 Three-Arm Design 75
3.4 The Noninferiority Margin and Regulatory Guidance 77
3.4.1 ICH Guidance 77
3.4.2 FDA Guidance 77
3.4.3 CHMP Guidance 79
3.5 Controversies and Challenges 81
3.5.1 Assay Sensitivity, Constancy and Biocreep 81
3.5.2 Conflicting Noninferiority-Superiority Claims 81
3.5.3 Dilemma of Totality Evidence 82
3.5.4 Superiority-Noninferiority Testing 83
3.5.5 Summary 83
3.6 Exercises 84
Further Readings and References 85

4 Adaptive Trial Design 87
4.1 Concept of Adaptive Trial Design 87
4.1.1 Reasons for Adaptive Design 87
4.1.2 Hypothesis-Based Adaptive Design 88
4.2 Adaptive Design Methods 92
4.2.1 p-value Weighting Approach 92
4.2.2 Fisher Combination Approach 94
4.2.3 p-value Inversion Approach 95
4.2.4 Error-Spending Approach 96
4.3 Evaluation and Analysis of Adaptive Design 97
4.3.1 Evaluation Matrix 97
4.3.2 Analysis of Adaptive Trial Data 99
4.3.3 Comparison of Adaptive Design Methods 102
4.4 Adaptive Designs in Action 105
4.4.1 Sample Size Reestimation 105

4.4.2 Adaptive Seamless Design 107
4.4.3 Noninferiority-Superiority Adaptive Design 108
4.5 Adaptive Design Debates 109
4.5.1 Sufficiency Principle 109
4.5.2 Minimum Sufficiency Principle and Efficiency 110
4.5.3 Conditionality and Exchangeability Principles 110
4.5.4 Equal Weight Principle 111
4.5.5 Consistency of Stagewise Results 111
4.5.6 Adjusted p-value 112
4.5.7 Summary 112
4.6 Exercises 113
Further Readings and References 114

5 Missing Data Imputation and Analysis 117
5.1 Missing Data Problems 117
5.1.1 Missing Data Issue and Its Impact 117
5.1.2 Missing Data Taxonomy 118
5.2 Analysis Methods for Missing at Random 120
5.2.1 Single Imputation Methods 120
5.2.2 Generalized Linear Mixed Models 120
5.2.3 Expectation-Maximization Algorithm 122
5.2.4 Inverse-Probability Weighting Method 123
5.2.5 Multiple-Imputation Method 125
5.2.6 Weighted Generalized Estimating Equations 126
5.3 Analysis Methods for Missing Not at Random 128
5.3.1 Missing Data Frameworks 128
5.3.2 Selection Model 130
5.3.3 Pattern-Mixture Model 131
5.3.4 Shared-Parameter Models 131
5.4 Analysis Examples Using SAS and SOLAS 133
5.4.1 Likelihood Ignorable Analysis 134
5.4.2 Multiple-Imputation Method 134
5.4.3 EM Algorithm Using SAS 136
5.4.4 SOLAS for Missing Data Analysis 136
5.5 Controversies, Challenges, and Recommendations 137
5.5.1 Comparisons of Different Methods 137
5.5.2 How to Implement Missingness 138
5.5.3 Regulatory Perspective 139
5.5.4 Recommendations for Clinical Trials 140
5.6 Exercises 142
Further Readings and References 142

6 Multivariate and Multistage Survival Data Modeling 145
6.1 Introduction to Survival Data Modeling 145
6.1.1 Basic Terms in Survival Analysis 145
6.1.2 Maximum Likelihood Method 146
6.1.3 Overview of Survival Model 147

6.2 Frailty Model 151
6.2.1 Univariate Frailty Models 151
6.2.2 Multivariate Frailty Models 152
6.2.3 The Shared Frailty Copula 152
6.2.4 The Correlated Frailty Copula 153
6.3 First-Hitting-Time Model 153
6.3.1 Wiener Process and First Hitting Time 153
6.3.2 Covariates and Link Function 154
6.3.3 Parameter Estimation and Inference 155
6.3.4 Applications of First-Hitting-Time Model 156
6.3.5 Multivariate Model with Biomarkers 157
6.4 Multistage Model 159
6.4.1 General Framework of Multistage Model 159
6.4.2 Covariates and Treatment Switching 161
6.4.3 Latent Process and Competing Risks 163
6.4.4 Competing Risks in Progressive Disease 167
6.4.5 Longitudinal Multivariate Model 169
6.5 Challenges and Controversies 170
6.6 Exercises 172
Further Readings and References 172

7 Meta-Analysis 175
7.1 Concept of Meta-Analysis 175
7.1.1 The Art and Science of Meta-Analysis 175
7.1.2 Study Endpoints 176
7.1.3 Basic Methods 179
7.2 Subject-Based Meta-Analysis 180
7.3 Study-Based Meta-Analysis 180
7.3.1 The Fixed-Effect Model 180
7.3.2 Assessing Heterogeneity 184
7.3.3 Random-Effect Model 184
7.3.4 Mixture Model for Relative Risk 186
7.4 Meta-Analysis in Complex Settings 190
7.4.1 Individual and Aggregate Data Mixtures 190
7.4.2 Mixture of Matched and Unmatched Pairs 193
7.4.3 p-value Combination Approaches 194
7.4.4 Cumulative Meta-Analysis 195
7.5 Graphical Presentations 197
7.5.1 Funnel Plots 197
7.6 Controversies and Challenges 198
7.6.1 Inclusion of Studies 198
7.6.2 Inclusion, Analysis, and Reporting Bias 199
7.6.3 Inconsistency in Weight Selection 200
7.7 Exercises 201
Further Readings and References 202

8 Data Mining and Signal Detection 205
8.1 Common Data Mining Methods 205
8.1.1 Supervised, Unsupervised, and Reinforcement Learning. 205
8.1.2 Link Analysis 206
8.1.3 Nearest-Neighbors Method 208
8.1.4 Kernel Method 209
8.1.5 Support Vector Machine 209
8.1.6 Tree Methods 210
8.1.7 Artificial Neural Network 213
8.1.8 Unsupervised to Supervised Learning 215
8.1.9 K-Means Algorithm 216
8.1.10 Genetic Programming 217
8.1.11 Cellular Automata Method 217
8.1.12 Agent-Based Models 218
8.2 Signal Detection and Analysis 219
8.2.1 Pharmacovigilance 219
8.2.2 Traditional Hypothesis Test 220
8.2.3 Sequential Probability Ratio Test 221
8.2.4 Disproportional Analysis 223
8.2.5 Group Sequential Method 226
8.2.6 Data Mining Approach 226
8.3 Challenges 227
8.4 Exercises 229
Further Readings and References 229

9 Monte Carlo Simulation 233
9.1 Random Number Generation 233
9.1.1 Inverse c.d.f Method 233
9.1.2 Acceptance-Rejection Methods 234
9.1.3 Markov Chain Monte Carlo 235
9.2 Clinical Trial Simulation 236
9.2.1 Adaptive Trial Simulation 236
9.2.2 Dynamic Drug Supply 238
9.2.3 Bootstrapping Methods 240
9.3 Molecular Design and Simulation 242
9.3.1 The Landscape of Molecular Design 242
9.3.2 The Drug-Likeness Concept 243
9.3.3 Molecular Docking 245
9.4 Biological Pathway Simulation 248
9.4.1 Biology Pathways 248
9.4.2 Petri Nets 249
9.4.3 Biological Pathway Simulations 251
9.5 PK and PD Modeling and Simulation 252
9.5.1 Pharmacokinetic Simulation 252
9.5.2 Pharmacodynamic Simulation 255

9.6 Implementation Challenges 257
9.7 Exercises 258
Further Readings and References 259

10 Bayesian Methods and Applications 261
10.1 Bayesian Paradigm 261
10.1.1 Bayesian Inference 261
10.1.2 Model Selection 266
10.1.3 Hierarchical Model 267
10.1.4 Bayesian Decision-Making 268
10.1.5 Bayesian Approach to Multiplicity 269
10.1.6 Bayesian Computation 272
10.2 Applications of Bayesian Methods 275
10.2.1 Clinical Trial Design 275
10.2.2 Bayesian Adaptive Trial 276
10.2.3 Safety Signal Detection 279
10.2.4 Missing-Data Handling 281
10.2.5 Meta-Analysis 281
10.2.6 Noninferiority Design 282
10.2.7 Disease Mapping 284
10.3 Controversies and Debates 284
10.3.1 Internal Consistency 285
10.3.2 Subjectivity 287
10.4 Exercises 287
Further Readings and References 288

Index 291